Nuwellis Inc vs Health Care Select Sector SPDR Fund — how do they compare? Nuwellis Inc trades at $1.4 (market cap $542.80K), while Health Care Select Sector SPDR Fund trades at $168.63. The key difference: Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| NUWE | XLV | |
|---|---|---|
Market Cap | $542.80K | — |
Sector | Technology | — |
52-Week High | $220.50 | $168.44 |
52-Week Low | $1.42 | $131.16 |
Enterprise Value | -$1.27M | — |
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $1.43, up 0.7% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported a net loss of -$17.52M in 2025, with a negative net income margin of -217.22%, though recent news highlights product development and revenue growth initiatives, including a 14% preliminary year-over-year revenue increase in Q2 2026.
Outlook is cautious due to persistent losses and high cash burn, but growth in pediatric installations and strategic expansions offer potential. Risks include financial sustainability and competitive pressures, while analyst coverage is limited with a split buy/hold consensus.
XLV, the Health Care Select Sector SPDR ETF, trades at $167.1, down 0.8% on the day. The technical outlook is bullish based on moving averages, though short-term oscillators signal overbought conditions. Recent news highlights the ETF's defensive appeal amid economic uncertainty and its competitive edge with a low 0.08% expense ratio. Strong healthcare earnings and investor inflows into defensive sectors support positive momentum.
The outlook for XLV is positive, driven by defensive sector demand and solid underlying holdings. Key opportunities include cost efficiency and diversification across 60 healthcare stocks. Risks involve sector-specific pressures like regulatory changes and liquidity challenges. Analyst sentiment remains favorable, with the ETF well-positioned for steady growth in a volatile market.
Trailing returns across standard periods
Latest headlines on both assets
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →